SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention ahead of topline survival results from its Phase 3 REGAL trial of GPS, after the trial reached its 80th-event milestone; traders are also watching SLS009 data expected at ASH. Many holders are buying or staying invested in anticipation of positive results, while skeptics point to the stocks sharp declines and warn that the trial outcome remains uncertain.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris strong Q3 results, led by rapid Recorlev growth, a higher full-year revenue outlook and a raised 2030 target, have driven a sharp rally and expectations of further analyst upgrades. Traders are broadly bullish on the growth trajectory, while takeover and bidding-war talk remains speculative and unconfirmed.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Discussion centers on a product shown at Foxconns Tech Day and POETs presence in Foxconns photonics ecosystem, which traders view as validation of the optical-engine partnership and a possible step toward commercialization. Bulls are anticipating orders and production updates, while skeptics stress that a demonstration is not proof of purchase orders or scaled shipments.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys engine, technology-licensing and engineering-support agreement with AST SpaceMobile for its planned heavy-lift rocket is driving attention, with traders viewing it as a major validation of Fireflys propulsion business and a boost to its backlog and funding outlook. Some remain cautious about the AST shares included in the deal, potential dilution, execution risks and the upcoming earnings report.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklos sharp rebound is being tied to its Q3 update, including a reported earnings beat and an agreement to reserve manufacturing capacity for future reactor components. Traders are split between viewing the supply-chain and nuclear-development progress as a positive signal and arguing that the companys limited revenue, long commercialization timeline, and insider selling and dilution concerns make the bounce fragile.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs stronger-than-expected quarterly results and raised full-year revenue outlook are driving attention, with traders highlighting growth, backlog and momentum across quantum stocks. The reaction is broadly upbeat, though skeptics question cash burn, dilution and how much growth reflects acquisitions rather than the core quantum business.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Anticipation around Netlists Q3 earnings and call is driving attention, with traders watching for guidance and speculating about an SK hynix agreement or Nasdaq uplisting. The Kingston-related ITC complaint is also fueling hopes for further licensing, though some traders caution that broad memory-sector weakness and high expectations could limit the market reaction.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

AMPX is drawing attention after a sharp rebound from a recent selloff, alongside call-heavy options activity and a broader rebound in electrical-equipment and data-center infrastructure stocks. Traders are split on whether the move marks a lasting recovery or a short-term bounce, with the upcoming earnings report also in focus.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins pullback below the mid-$70,000s and heavy spot-ETF outflows are driving attention to IBIT, with traders debating whether the weakness signals further downside or a buying opportunity. Some see support holding and expect a rebound, while others point to redemptions and warn the selloff may continue.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

LUNRs sharp rebound after a steep selloff has traders debating whether short covering and a broader space-sector bounce are driving the move. Some speculate that NASAs upcoming CLPS 2.0 awards or other contract news could provide a catalyst, while others view the rally as temporary; no specific new award is confirmed in the discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The decline appears tied mainly to a broad market and biotech selloff, with uncertainty amplified as investors await topline results from SELLASs Phase 3 REGAL trial after it reached the 80th event. Community discussion points to no new negative company-specific disclosure, but the trials pending readout remains a key source of volatility.

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas 

Equity

Prospera increased its stake nearly 70%, while Eversource trimmed its position 42% and Nemes Rush held steady.

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4 

The Phase 2 study evaluated SLS009 alongside Azacitidine and Venetoclax in 62 patients with AML.


SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets 

ASH will release regular meeting abstracts on Wednesday, followed by late-breaking abstracts on Dec.7.

SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data — Fresh Filings Show Q3 Stake Hikes Of Over 400% 

Kestra raised its stake by 256% and Principal Financial by 61%, while Commonwealth and Cambridge trimmed holdings.

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus 

AstraZeneca emphasized ADC combinations, cell therapies and internally developed cancer vaccines as key oncology priorities.

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.

Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus

Markets are headed for a mixed close in October, with the Nasdaq likely to end lower, while the Dow and S&P 500 are headed to close in the green.

SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?

Retail bulls discussed buying the dip and a potential buyout, while others also challenged survival estimates.

Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18%

Sellas said that its Phase 3 Regal trial of GPS recorded its 80th event, triggering the final analysis.


SELLAS Life Sciences Stock Stumbles: What's Going On?

SELLAS Life Sciences Group shares are falling Wednesday as the company's Phase 3 leukemia study moves toward its final analysis.read more...

Bullish Sentiment

<ul class="summary-bullets"><li>Citigroup cut its holding by 64% to 119,036 shares, worth about $1.47 million at September-end.</li><li>SLS009’s completed Phase 2 study showed a 34% response rate among 59 evaluable AML patients.</li><li>Sellas expects Q4 results from its 80-patient frontline SLS009 study and Phase 3 Regal trial, which reached its 80th event last week.</li></ul>Shares of Sellas Life Sciences (SLS) rose 0.4% overnight late Wednesday as Citigroup disclosed a nearly 64% cut in its stake, while retail bulls argued that SLS009 alone could be worth more than the company.<a class="mention" data-mention="$SLS" data-symbol-id="SLS" href="https://stocktwits.com/symbol/SLS" target="_blank">SLS stock</a> rose 3% on Wednesday to $9.14, with shares still down nearly 6% for the week.&nbsp;<h2 class="st-heading-2">Citi Slashes SLS Stake, Other Investors Split&nbsp;</h2>Citigroup cut its Sellas holding by nearly two-thirds in the third quarter, reducing its position by 207,555 shares, or 64%, to 119,036 shares as of Sept.30, according to Fiscal.ai data on Wednesday’s disclosures. The remaining stake was worth about $1.47 million at quarter-end.&nbsp;Meanwhile, Prospera Financial Services added 12,600 shares, increasing its holding by nearly 70% to 30,719. Eversource Wealth Advisors trimmed its position by roughly 42% to 5,785 shares, while Nemes Rush Group kept its holding unchanged at 10,000 shares.<h2 class="st-heading-2">SLS009 Heads To ASH With Fresh AML Results</h2>The developments come as Sellas shared Phase 2 results for SLS009, also called Tambiciclib, ahead of a Dec.14 presentation at the American Society of Hematology (ASH) meeting in New Orleans.The study tested SLS009 with Azacitidine and Venetoclax in 62 previously treated AML patients whose leukemia had returned or stopped responding to venetoclax-based treatment. Across doses, 34% of the 59 patients assessed responded. At the selected dose, 54% of patients with monocytic AML responded, with median survival of 5.8 months. For TP53-mutated AML, the response rate was 57% and median survival was 8.8 months.Sellas reported limited added toxicity and cited historical survival of about 2.5 months in these high-risk groups. Without a concurrent comparison group, however, the figures do not prove a survival benefit.The company is also exploring SLS009 beyond leukemia. In September, it reported activity in laboratory models of pancreatic cancer, although those early findings have yet to establish benefit in patients.<h2 class="st-heading-2">Sellas Nears A 2-Trial Data Test</h2>CEO Angelos Stergiou highlighted the SLS009 findings in a recent&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7523746541346508800&amp;highlightedUpdateType=SHARED_BY_YOUR_NETWORK&amp;origin=inapp&amp;showCommentBox=true">LinkedIn post</a>, while drawing attention to two upcoming data announcements. “These are some of the hardest-to-treat patients in hematology. Seeing this level of activity is exactly why we do this work,” he said.Sellas expects initial results this quarter from its ongoing 80-patient Phase 2 study of SLS009 in newly diagnosed AML. This readout is separate from the completed study being presented at ASH. Stergiou also reiterated that results from the Phase 3 Regal trial of Galinpepimut-S (GPS) are expected soon.Regal reached its prespecified 80th patient death on Oct. 28, triggering the process of locking the database, unblinding treatment assignments and analyzing the final results. The randomized trial is testing whether GPS maintenance treatment helps AML patients live longer after achieving a second complete remission. Preliminary results are expected this quarter.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS slipped to ‘bullish’ from ‘extremely bullish’ levels a week ago amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_3712f83192.png" alt="sls ss.png" width="644" height="333"><figcaption>SLS sentiment and message volume as of November 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Bio_buyout/message/668064034https://stocktwits.com/Bio_buyout/message/668064034">said</a>, “009 is not valued for a penny in the market cap.” They added that the asset alone should be worth five times Sellas’ valuation.<stembedurl>https://stocktwits.com/Bio_buyout/message/66806403</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/55X_ROI_Q1_2026/message/668207113">put&nbsp;</a>SLS009’s standalone value above $5 billion.A separate user&nbsp;<a href="https://stocktwits.com/Nasfact/message/668203058">said&nbsp;</a>that successful SLS009 frontline results could support a buyout even if GPS disappointed. “Two platforms on goal on multiple indications! I like the odds!” the user said. Another user urged investors to look beyond a single leukemia indication,&nbsp;<a href="https://stocktwits.com/Duncan74/message/668213107">saying</a>, “The platform valuation is the true forest. AML revenue is just the initial tree.”SLS stock has risen 142% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-spacex-40b-chip-financing-market-texas-senator-democrats-go-after-elon-musk/cNG1bF6R9Ed">SPCX Slides Overnight: SpaceX’s $40B Chip Financing Reportedly Hits Market — Texas Senator Says Democrats Will ‘Go After Elon Musk’&nbsp;</a>

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas

iShares Biotechnology ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

$TMDX

$SLS

Which of these trending stocks are you most tempted to buy - $ON, $TMDX, $SLS, or $BE?

Current Price	$8.42
Prev Close	$7.88
Open	$8.03
Dividend Yield	0.00%
50-Day Moving Average	$11.69
Beta	0.99
Avg. Volume	6.59M
PE Ratio	-37.13

52-Week High	$15.88
52-Week Low	$1.39
Market Capitalization	$1.59B
EPS (Annual)	-$0.2463
Price to Book	11.56
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLS Fundamentals